Incyte clinical trial pipeline

Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single…Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants

Trial status changed: Not Yet Recruiting → Active, Not Recruiting

Incyte Corporation·Phase 1· NCT07814404· Registry history of NCT07814404 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026

Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study…Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

Trial completed

Incyte Corporation·Phase 1· NCT07588139· Registry history of NCT07588139 on ClinicalTrials.gov (opens the registry)

Oct 9, 2026

INCB000928 Administered as a Monotherapy or in Combination With…INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib · Anemia Due to Myeloproliferative Disorders

Trial completed

Also in this update: Study completion date changed from estimate of Nov 26, 2027 to Sep 8, 2026

Incyte Corporation·Phase 1/2· NCT04455841· Registry history of NCT04455841 on ClinicalTrials.gov (opens the registry)

Oct 1, 2026

Retinfanlimab in Combination With INCAGN02385 and INCAGN02390…Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment · PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial completed

Incyte Biosciences International Sàrl·Phase 2· NCT05287113· Registry history of NCT05287113 on ClinicalTrials.gov (opens the registry)

Sep 25, 2026

MAESTRA 2 · INCB123667 Versus Investigator's Choice of…MAESTRA 2 · INCB123667 Versus Investigator's Choice of Chemotherapy · Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Trial sites expanded: 192 → 197 locations

Incyte Corporation·Phase 3· NCT07214779· Registry history of NCT07214779 on ClinicalTrials.gov (opens the registry)

Oct 9, 2026

AXemplify-357 · Axatilimab and Corticosteroids as Initial…AXemplify-357 · Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Trial sites expanded: 128 → 131 locations

Incyte Corporation·Phase 3· NCT06585774· Registry history of NCT06585774 on ClinicalTrials.gov (opens the registry)

Oct 9, 2026

Standard-of-Care Chemotherapy and Bevacizumab With or Without…Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Trial sites expanded: 280 → 293 locations

Incyte Corporation·Phase 3· NCT07284849· Registry history of NCT07284849 on ClinicalTrials.gov (opens the registry)

Oct 9, 2026

EXCALIBUR-ET2 · INCA033989 Versus Best Available Therapy…EXCALIBUR-ET2 · INCA033989 Versus Best Available Therapy · Essential Thrombocythemia

Trial sites expanded: 175 → 178 locations

Incyte Corporation·Phase 3· NCT07623200· Registry history of NCT07623200 on ClinicalTrials.gov (opens the registry)

Oct 8, 2026

THRIVE · Patients at Risk for Chronic Graft-Versus-Host Disease

Trial sites expanded: 32 → 37 locations

Incyte Corporation·Not specified· NCT05919511· Registry history of NCT05919511 on ClinicalTrials.gov (opens the registry)

Oct 6, 2026

Axatilimab in Combination With Ruxolitinib · Newly Diagnosed…Axatilimab in Combination With Ruxolitinib · Newly Diagnosed Chronic Graft-Versus-Host Disease

Study completion moved earlier from Dec 1, 2029 to Mar 30, 2029

Also in this update: Primary completion date changed from estimate of Jun 1, 2027 to Oct 1, 2026

Incyte Corporation·Phase 2· NCT06388564· Registry history of NCT06388564 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026